Background Serotonergic mechanisms play a key role in the development of the Levodopa-induced dyskinesias (LIDs) in patients with Parkinson's disease (PD). We hypothesised that an unfavourable serotonin-to-dopamine terminal ratio in the putamen would be most detrimental in dyskinetic patients. We investigated the role of serotonin-to-dopamine transporter binding ratios in the development of dyskinesias in Parkinson's disease patients.
Methods/Subjects Twenty-eight Parkinson's disease patients[17 with LIDs;11 stable] and 12 age and gender-matched healthy controls were studied with [11C]DASB PET and [123I]FP-CIT SPECT, Imaging. We have employed a simplified reference tissue model using cerebellar reference for the quantification of [11C]DASB, whereas a semi-quantification approach was used for [123I]FP-CIT. We estimated uptake values in the putamen.
Results Parkinson's disease patients showed decreases in [123I]FP-CIT binding (p<0.001) compared to controls, 51% in the stable and 62% in the LIDs group. PD patients showed decreases in [11C]DASB binding (p<0.01), but there were no differences between the stable (37% loss) and LIDs(31% loss) groups. PD patients with LIDs had 103% increased [11C]DASB-to-[123I]FP-CIT binding ratio, whereas in the PD stable group the ratio was increased by 76%, relative to HCs. Higher [11C]DASB-to-[123I]FP-CIT binding ratio correlated with longer disease duration for the 28 PD patients (r=0.52;p<0.01).
Conclusion SERT-to-DAT ratio increases as PD progresses and patients experience LIDs.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.